Treating with the SS1 TriKE during exposure to hypoxia and upon tumor challenge maximized both IL-15 delivery and tumor-targeting mechanisms to provide the greatest benefit relative to IL-15 alone (fig. This evidence concerns the gene IL15 and neoplasm.